pfizer_finland_hq

Pfizer drug beats AZ rival in halting lung cancer

pharmafile | June 6, 2017 | News story | Manufacturing and Production, Research and Development NSCLC, Pfizer 

New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression of EGFR-positive non-small cell lung cancer (NSCLC), albeit with a higher prevalence of side-effects.

Like older treatments, dacomitinib targets abnormal epidermal growth factor receptor genes in advanced lung cancer. In a study of 452 patients, Pfizer’s drug exhibited the ability to delay the progression of cancer for 14.7 months, compared to 9.2 months for AZ’s Ingressa – a 41% improvement.

However, these promising statistics also coincided with increased incidence of acne, diarrhoea, and liver enzyme abnormalities as a result of the drug’s suppression of EGFR genes in the skin and gastrointestinal tract, causing 60% of participants to have their dose lowered. However, despite this,

Lead Researcher Dr Tony Mok, from the Chinese University of Hong Kong, commented: “the activity seen in this study should allow for consideration of this effective therapy in this patient population.”

EGFR-positive NSCLC affects around 140,000 patients worldwide. Pfizer has announced that it now plans to speak with regulatory agencies to secure approval for the drug.

Matt Fellows

Related Content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

Latest content